FDA Extends Funding for Palvella’s QTORIN Rapamycin as NDA Submission Nears
Event summary
- FDA awarded Palvella a third year of grant funding for QTORIN rapamycin, supporting Phase 3 SELVA trial and open-label extension study.
- Positive Phase 3 SELVA trial results met all primary and secondary endpoints with statistical significance (p<0.001).
- NDA submission completed in August 2026; potential U.S. commercial launch in H1 2027 if approved.
- QTORIN rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, targeting ~30,000 U.S. patients.
The big picture
Palvella’s continued FDA support underscores the strategic importance of QTORIN rapamycin in addressing an unmet need for microcystic lymphatic malformations. The potential approval could set a new standard of care, positioning Palvella as a key player in the rare disease space. The Phase 3 trial’s success highlights the growing emphasis on targeted therapies for vascular anomalies, a segment with limited FDA-approved options.
What we're watching
- Regulatory Approval
- Whether the FDA will approve QTORIN rapamycin by H1 2027, given the positive Phase 3 results and Breakthrough Therapy designation.
- Commercial Readiness
- The pace at which Palvella can prepare for a potential U.S. launch, given the competitive landscape for rare disease therapies.
- Pipeline Progress
- How Palvella’s second product candidate, QTORIN pitavastatin, advances alongside QTORIN rapamycin’s regulatory path.